PMID- 35082928
OWN - NLM
STAT- MEDLINE
DCOM- 20220323
LR  - 20220430
IS  - 1875-8630 (Electronic)
IS  - 0278-0240 (Print)
IS  - 0278-0240 (Linking)
VI  - 2022
DP  - 2022
TI  - Associations of Genetic Polymorphisms of mTOR rs2295080 T/G and rs1883965 G/A 
      with Susceptibility of Urinary System Cancers.
PG  - 1720851
LID - 10.1155/2022/1720851 [doi]
LID - 1720851
AB  - BACKGROUND: Genetic polymorphisms in mammalian target of rapamycin (mTOR) 
      signaling axis can influence the susceptibility of cancer. The relationship 
      between mTOR gene variants rs2295080 T/G and rs1883965 G/A and the risk of cancer 
      remains inconsistent. The present study is aimed at comprehensively investigating 
      the association between mTOR polymorphisms and susceptibility to cancer. METHODS: 
      We conducted a comprehensive assessment using odds ratios (ORs), corresponding 
      95% confidence intervals (CIs), and in silico tools to evaluate the effect of 
      mTOR variations. Immunohistochemical staining (IHS) and GSEA analysis were used 
      to investigate the expression of mTOR in urinary system cancer. RESULTS: The 
      pooled analysis involved 22 case-control studies including 14,747 cancer patients 
      and 16,399 controls. The rs2295080 T/G polymorphism was associated with the risk 
      of cancer (G-allele versus T-allele, OR = 0.89, 95%CI = 0.80-0.98, P = 0.023; GT 
      versus TT, OR = 0.88, 95%CI = 0.81-0.96, P = 0.004; GG+GT versus TT, OR = 0.87, 
      95%CI = 0.78-0.96, P = 0.008), especially for cancers of the urinary system, 
      breast, and blood. Variation rs1883965 G/A was associated with cancer 
      susceptibility, especially for digestive cancer. IHS analysis showed that mTOR 
      was upregulated in prostate and bladder cancer. GSEA revealed that the insulin 
      signaling pathway, lysine degradation pathway, and mTOR signaling pathway were 
      enriched in the high mTOR expression group. CONCLUSIONS: The mTOR rs2295080 T/G 
      polymorphism may be associated with susceptibility of urinary cancer. The 
      expression of mTOR is positively correlated with tumor malignancy in prostate 
      cancer.
CI  - Copyright (c) 2022 Zhichao Min et al.
FAU - Min, Zhichao
AU  - Min Z
AD  - Department of Urology, The First People's Hospital of Hangzhou Lin'an District, 
      Hangzhou 310000, China.
FAU - Mi, Yuanyuan
AU  - Mi Y
AD  - Department of Urology, Affiliated Hospital of Jiangnan University, Wuxi 214000, 
      China.
FAU - Lv, Zhiwei
AU  - Lv Z
AD  - Department of Urology, The Affiliated Changzhou No. 2 People's Hospital of 
      Nanjing Medical University, 29 Xinglong Road, Changzhou 213003, China.
FAU - Sun, Yangyang
AU  - Sun Y
AD  - Department of Pathology, The Affiliated Changzhou No. 2 People's Hospital of 
      Nanjing Medical University, 29 Xinglong Road, Changzhou 213003, China.
FAU - Tang, Bowen
AU  - Tang B
AD  - Department of Urology, The Affiliated Changzhou No. 2 People's Hospital of 
      Nanjing Medical University, 29 Xinglong Road, Changzhou 213003, China.
FAU - Wu, Hao
AU  - Wu H
AD  - Department of Urology, The Affiliated Changzhou No. 2 People's Hospital of 
      Nanjing Medical University, 29 Xinglong Road, Changzhou 213003, China.
FAU - Zhang, Ze
AU  - Zhang Z
AD  - Department of Urology, The Affiliated Changzhou No. 2 People's Hospital of 
      Nanjing Medical University, 29 Xinglong Road, Changzhou 213003, China.
FAU - Pan, Hong
AU  - Pan H
AD  - Department of Operation Theatre, The Affiliated Changzhou No. 2 People's Hospital 
      of Nanjing Medical University, 29 Xinglong Road, Changzhou 213003, China.
FAU - Zhang, Yujuan
AU  - Zhang Y
AD  - Department of Operation Theatre, The Affiliated Changzhou No. 2 People's Hospital 
      of Nanjing Medical University, 29 Xinglong Road, Changzhou 213003, China.
FAU - Lu, Chao
AU  - Lu C
AUID- ORCID: 0000-0001-8857-0523
AD  - Department of Urology, The Affiliated Changzhou No. 2 People's Hospital of 
      Nanjing Medical University, 29 Xinglong Road, Changzhou 213003, China.
FAU - Zuo, Li
AU  - Zuo L
AUID- ORCID: 0000-0002-3668-004X
AD  - Department of Urology, The Affiliated Changzhou No. 2 People's Hospital of 
      Nanjing Medical University, 29 Xinglong Road, Changzhou 213003, China.
FAU - Zhang, Lifeng
AU  - Zhang L
AUID- ORCID: 0000-0003-2236-9936
AD  - Department of Urology, The Affiliated Changzhou No. 2 People's Hospital of 
      Nanjing Medical University, 29 Xinglong Road, Changzhou 213003, China.
LA  - eng
PT  - Journal Article
DEP - 20220117
PL  - United States
TA  - Dis Markers
JT  - Disease markers
JID - 8604127
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Alleles
MH  - Genetic Predisposition to Disease/genetics
MH  - Genotype
MH  - Humans
MH  - Polymorphism, Single Nucleotide/*genetics
MH  - Promoter Regions, Genetic/genetics
MH  - TOR Serine-Threonine Kinases/*genetics
MH  - Urologic Neoplasms/*genetics
PMC - PMC8786550
COIS- The authors declare no conflict of interests.
EDAT- 2022/01/28 06:00
MHDA- 2022/03/24 06:00
PMCR- 2022/01/17
CRDT- 2022/01/27 05:49
PHST- 2021/05/07 00:00 [received]
PHST- 2021/12/18 00:00 [accepted]
PHST- 2022/01/27 05:49 [entrez]
PHST- 2022/01/28 06:00 [pubmed]
PHST- 2022/03/24 06:00 [medline]
PHST- 2022/01/17 00:00 [pmc-release]
AID - 10.1155/2022/1720851 [doi]
PST - epublish
SO  - Dis Markers. 2022 Jan 17;2022:1720851. doi: 10.1155/2022/1720851. eCollection 
      2022.